despit
appar
bland
collect
mindset
import
portion
societi
intrins
morbid
mortal
well
relat
death
bacteri
superinfect
exacerb
chronic
ill
make
influenza
infect
major
recurr
global
public
health
concern
inde
human
influenza
type
b
virus
respons
annual
flu
epidem
mark
billion
infect
million
sever
case
death
worldwid
huge
econom
burden
term
medic
visit
hospit
workschool
absente
product
loss
member
orthomyxovirida
famili
influenza
virus
type
b
c
envelop
virus
harbor
negativesens
singlestrand
rna
segment
genom
segment
natur
viral
genom
resid
capac
influenza
virus
form
new
reassort
strain
follow
concomit
infect
host
one
strain
human
andor
anim
origin
phenomenon
far
observ
among
type
influenza
virus
review
owe
viral
reassort
genet
baggag
progeni
virus
exactli
match
one
parent
strain
combin
depend
specif
combin
genet
segment
notabl
case
human
influenza
strain
acquir
hemagglutinin
ha
andor
neuraminidas
na
major
surfac
antigen
anim
origin
reassort
event
result
antigen
shift
defin
gener
new
viru
antigen
properti
drastic
differ
circul
strain
new
variant
suffici
antigen
differ
escap
repertoir
preexist
immun
popul
might
rapidli
dissemin
replac
circul
strain
henc
trigger
global
influenza
pandem
although
rel
verit
pandem
occur
centuri
one
far
twentyfirst
outbreak
pandem
quit
unpredict
event
might
entail
potenti
devast
effect
review
particularli
consid
contemporari
state
affair
regard
global
transport
trade
migrat
narrow
interfac
rural
overcrowd
urban
area
influenza
vaccin
constitut
effect
strategi
prevent
season
flu
clinic
complic
mainli
among
highrisk
popul
young
children
elderli
pregnant
women
immunocompromis
patient
well
peopl
obes
diabet
cardiorespiratori
comorbid
nevertheless
current
flu
vaccin
still
present
sever
limit
make
fall
short
expect
term
effect
short
durat
vaccineinduc
immun
coupl
intrins
antigen
drift
influenza
virus
result
gradual
accumul
point
mutat
antigen
site
ha
lesser
extent
na
surfac
protein
underscor
need
annual
reformul
vaccin
composit
moreov
length
current
vaccin
manufactur
process
least
month
produc
suffici
larg
vaccin
quantiti
demand
continu
strain
select
done
approxim
month
next
flu
season
antigen
drift
occur
time
window
possibl
mismatch
vaccin
composit
circul
strain
might
neg
affect
protect
even
absenc
season
mismatch
emerg
pandem
strain
insuffici
vaccin
coverag
suboptim
uptak
specif
target
group
ie
elderli
immunocompromis
also
compromis
vaccin
effect
furthermor
despit
recent
progress
made
pursu
holi
grail
univers
influenza
vaccin
provid
broader
longlast
protect
match
antigen
divers
influenza
strain
clinic
effect
remain
evalu
henc
highlight
need
complementari
therapeut
approach
manag
influenza
infect
besid
vaccin
antivir
drug
repres
pillar
control
season
influenza
epidem
play
central
role
major
prophylact
therapeut
agent
event
pandem
outbreak
regard
review
summar
stateoftheart
current
antivir
option
influenza
infect
particular
focu
recent
advanc
antiinfluenza
drug
repurpos
strategi
potenti
therapeut
regulatori
econom
benefit
review
present
exampl
multipl
way
reposit
molecul
treatment
influenza
adventiti
discoveri
silicobas
screen
novel
antivir
candid
mani
target
host
cell
could
also
use
combin
convent
virustarget
antivir
agent
order
reinforc
limit
therapeut
arsen
influenza
viru
infect
mention
antivir
key
player
pandem
prepared
program
first
choic
treatment
infect
patient
well
prevent
postexposur
prophylaxi
potenti
expos
new
viru
especi
initi
pandem
period
vaccin
avail
antivir
well
import
normal
season
set
although
use
mostli
focus
treatment
sever
ill
patient
immunocompromis
countri
includ
usa
japan
regularli
resort
antivir
manag
uncompl
influenza
otherwis
healthi
patient
date
two
class
antivir
agent
global
approv
avail
treatment
influenza
infect
ionchannel
blocker
neuraminidas
na
inhibitor
first
class
includ
adamantan
deriv
amantadin
rimantadin
inhibit
proton
conduct
ion
channel
influenza
virus
henc
prevent
viral
uncoat
step
viral
replic
cycl
nevertheless
although
quit
effici
earli
day
widespread
dissemin
much
lesser
extent
resist
mutat
circul
strain
prompt
remov
amantadin
rimantadin
list
recommend
antiinfluenza
agent
clinic
use
result
na
inhibitor
stand
influenza
antivir
current
recommend
na
inhibitor
competit
analog
sialic
acid
prefer
influenza
receptor
host
cell
surfac
bind
broadli
conserv
activ
site
na
na
inhibitor
interfer
sialidas
enzymat
activ
viral
protein
essenti
releas
newli
form
progeni
virus
infect
cell
henc
prevent
spread
infect
rest
respiratori
tissu
three
na
inhibitor
current
licens
worldwid
treatment
influenza
b
infect
oseltamivir
zanamivir
peramivir
oral
oseltamivir
administ
prodrug
oseltamivir
phosphat
larg
use
three
wherea
inhal
zanamivir
recommend
young
children
individu
underli
respiratori
condit
intraven
peramivir
priorit
hospit
patient
receiv
oral
treatment
addit
inhal
laninamivir
singledos
long
last
na
inhibitor
approv
japan
prevent
treatment
influenza
b
adult
pediatr
patient
import
note
degre
skeptic
still
present
regard
real
efficaci
na
inhibitor
notabl
follow
cochran
clinic
metaanalysi
report
minim
shorten
influenza
symptom
children
adult
uncompl
influenza
hospit
patient
nevertheless
actual
evidencebas
consensu
point
moder
efficaci
na
inhibitor
treatment
reduc
symptom
durat
pneumonia
hospit
mortal
especi
administ
within
h
symptom
onset
convers
delay
treatment
initi
associ
compromis
efficaci
may
yet
benefici
atrisk
patient
moreov
emerg
na
inhibitorresist
viru
variant
matter
concern
particularli
higher
frequenc
among
children
immunocompromis
na
substitut
main
mutat
respons
oseltamivir
peramivir
resist
virus
commonli
report
virus
latter
two
also
confer
reduc
suscept
zanamivir
laninamivir
even
nowaday
preval
drugresist
circul
strain
quit
low
evid
form
season
strain
prove
given
appropri
condit
resist
could
rapidli
dissemin
attain
preval
regard
rel
recent
detect
local
cluster
na
inhibitorresist
virus
harbor
mutat
combin
na
substitut
strengthen
import
continu
surveil
addit
ion
channel
blocker
na
inhibitor
two
small
molecul
target
viral
rnadepend
rna
polymeras
favipiravir
baloxavir
marboxil
undergo
clinic
evalu
us
europ
alreadi
obtain
approv
japanes
health
author
favipiravir
nucleosid
analog
act
competit
inhibitor
viral
polymeras
substrat
approv
sinc
treatment
influenza
infect
newli
emerg
strain
andor
resist
antivir
agent
howev
despit
appar
high
threshold
drug
resist
broadspectrum
antivir
potenti
notabl
valid
context
recent
ebola
viru
outbreak
recent
result
phase
iiiii
random
trial
therapeut
efficaci
uncompl
influenza
complet
conclus
baloxavir
marboxil
select
inhibitor
capdepend
endonucleas
activ
influenza
viral
pa
polymeras
subunit
therefor
interf
capsnatch
activ
viral
polymeras
complex
regard
recent
report
disclos
first
time
result
two
random
phase
ii
iii
clinic
trial
evalu
efficaci
singledos
oral
treatment
baloxavir
marboxil
otherwis
healthi
outpati
acut
uncompl
influenza
compar
placebo
regular
treatment
oseltamivir
overal
baloxavir
marboxil
oseltamivir
moder
reduc
time
symptom
allevi
compar
placebo
former
outperform
two
other
reduc
viral
load
result
prompt
us
food
drug
administr
fda
approv
baloxavir
marboxil
treatment
acut
uncompl
influenza
patient
year
age
older
symptomat
h
nevertheless
first
antivir
flu
treatment
novel
mechan
action
approv
fda
nearli
year
seem
escap
problem
virustarget
antiinfluenza
agent
emerg
viru
variant
mostli
due
pa
amino
acid
substitut
confer
signific
level
reduc
suscept
baloxavir
marboxil
observ
patient
receiv
drug
overal
tabl
summar
main
characterist
abovement
current
avail
antivir
option
influenza
limit
therapeut
arsen
coupl
recurr
risk
emerg
drugresist
highlight
obviou
unmet
need
novel
approach
complement
exist
therapi
new
antiinfluenza
drug
bestknown
success
stori
drug
repurpos
start
point
serendipit
observ
record
context
either
preclin
model
diseas
prepostapprov
clinic
trial
lead
subsequ
ration
evalu
valid
new
treatment
potenti
thalidomid
sildenafil
two
exampl
key
observ
first
one
initi
introduc
antinausea
pregnant
women
rapidli
remov
market
due
teratogen
research
enabl
molecul
well
deriv
repurpos
treatment
leprosi
multipl
myeloma
sildenafil
hand
never
reach
market
origin
intend
use
treatment
hypertens
observ
sideeffect
erectil
dysfunct
end
approv
commerci
name
recent
sildenafil
found
third
life
commerci
brand
treatment
pulmonari
hypertens
although
serendipit
observ
histor
prove
use
intrins
necess
casual
observ
unintend
usual
infrequ
second
benefit
pose
signific
hurdl
exploit
full
potenti
drug
repurpos
control
systemat
methodolog
need
targetbas
repurpos
reli
previou
knowledg
specif
molecular
cellular
determinantfunct
target
recogn
drug
intend
repurpos
new
research
find
target
play
import
role
condit
diseas
origin
indic
potenti
repurpos
note
target
might
necessarili
play
role
condit
exampl
case
previous
mention
favipiravir
drug
play
role
viral
rna
polymeras
inhibitor
influenza
ebola
virus
hand
abelson
tyrosineprotein
kinas
target
anticanc
drug
imatinib
found
requir
effici
fusion
releas
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
pseudovirion
cytoplasm
infect
cell
key
step
viral
replic
altern
scenario
targetbas
repurpos
happen
particular
drug
known
mechan
action
found
new
molecularcellular
target
previous
unrecogn
second
target
associ
differ
diseas
molecul
therefor
said
present
polypharmacologyrel
featur
mean
capac
act
multipl
target
polypharmacolog
phenomena
includ
singl
drug
act
multipl
target
uniqu
diseas
pathway
singl
drug
act
multipl
target
pertain
multipl
diseas
pathway
fact
polypharmacolog
usual
respons
treatment
toxic
undesir
advers
event
sideeffect
might
also
lead
drug
repurpos
exemplifi
next
section
last
decad
increas
number
studi
converg
propos
mani
drug
initi
design
uniqu
therapeut
target
fact
expect
hit
averag
differ
target
one
major
limit
targetbas
drug
repurpos
model
reli
depend
exist
scientif
knowledg
drugdiseas
mechan
actionpatholog
well
potenti
altern
target
usual
incomplet
word
fulli
anticip
repurpos
potenti
drug
unless
character
molecularcellular
target
know
given
drug
target
play
import
role
particular
diseas
phenotyp
screen
bioactiv
molecul
librari
differ
experiment
cellbas
vivo
diseas
model
without
need
priori
knowledg
consider
target
andor
mechan
action
candid
design
modul
provid
valuabl
contribut
overcom
constraint
inde
despit
approach
question
due
fact
expect
alter
phenotyp
readout
surrog
exploit
biolog
effect
induc
drug
candid
might
account
import
number
fals
posit
hit
nonetheless
true
contribut
highthroughput
phenotyp
screen
firstinclass
small
molecul
drug
discoveri
exceed
targetbas
approach
regard
mani
wellannot
collect
smallmolecul
librari
could
readili
made
avail
differ
collabor
andor
commerci
partnership
order
acceler
drug
repurpos
hypothesi
bias
unbias
phenotyp
screen
review
advent
big
data
system
biolog
computerbas
approach
gain
increas
accept
field
drug
discoveri
drug
repurpos
except
besid
inclus
constantli
emerg
omic
eg
transcriptom
proteom
metabolom
data
expand
current
knowledg
drugdiseaseassoci
mechan
silico
data
mine
model
tool
push
capac
analyz
data
next
level
silico
method
includ
screen
chemic
biolog
text
databas
analysi
quantit
structureact
relationship
pharmacophor
homolog
model
molecular
model
approach
well
network
analysi
biolog
function
machin
learn
almost
analysi
tool
includ
use
comput
regard
proper
mine
biolog
chemic
clinic
dataset
prove
effect
unveil
novel
relationship
moreov
anoth
level
complex
ad
combin
exampl
epidemiolog
inform
obtain
inhous
andor
publicli
avail
literatur
databas
vitro
experiment
molecul
screen
aim
identifi
novel
indic
case
digoxin
prostat
cancer
inde
real
power
computerassist
drug
repurpos
resid
adopt
integr
strategi
combin
predict
analyt
capac
silico
tool
target
bias
unbias
experiment
evaluationvalid
method
previous
mention
system
pharmacolog
approach
across
boundari
tradit
disciplin
would
put
research
betterinform
posit
design
comprehens
repurpos
strategi
effect
predict
capac
hope
improv
candid
success
rate
last
year
remark
grow
interest
drug
repurpos
field
antivir
drug
discoveri
fuel
incontest
realiti
mani
known
viral
infect
still
lack
specif
treatment
interest
invers
correl
low
number
classic
antivir
molecul
marketapprov
last
year
mostli
treatment
hepat
c
viru
hivrel
patholog
best
exampl
antivir
drug
repurpos
approach
emerg
virus
ebola
zika
viru
merscov
urgent
costeffect
need
therapeut
solut
inde
rapidli
propos
solut
context
viral
outbreak
one
interest
approach
consist
look
avail
pharmacopeia
use
treat
pathogen
exampl
chloroquin
major
antimalari
drug
propos
treatment
filovir
infect
larg
treatment
emerg
pathogen
target
endosom
acidif
pivot
step
replic
cycl
larg
number
virus
anoth
interest
illustr
previous
cite
exampl
favipiravir
prove
repurpos
potenti
treatment
zika
ebola
viral
infect
mention
intrins
everevolv
natur
viru
high
transmiss
host
promiscu
suboptim
vaccin
efficaci
limit
antivir
arsen
zoonot
pandem
potenti
convinc
factor
consid
influenza
virus
attract
target
drug
repurpos
despit
mani
interest
omicsbas
approach
highthroughput
screen
specif
drug
librari
kinas
inhibitor
antiinfluenza
agent
issu
drug
repurpos
yet
reach
regulatori
market
approv
howev
advanc
made
last
year
forecast
optim
follow
select
exampl
constitut
good
illustr
divers
capabl
drug
repurpos
strategi
influenza
infect
exhaust
list
antiinfluenza
candid
issu
drug
repurpos
approach
present
tabl
case
statin
arguabl
bestknown
exampl
antiinfluenza
repurpos
issu
clinic
observ
earli
clinician
observ
besid
cardioprotect
activ
statin
hydroxyl
methylglutarylcoenzym
hmgcoa
reductas
inhibitor
approv
use
cholesterol
metabol
regul
could
pleiotrop
antiinflammatori
immunomodulatori
effect
could
benefit
improv
surviv
patient
sever
influenza
although
mani
mous
observ
studi
account
protect
role
statin
pneumonia
vivo
studi
report
far
fail
clearli
demonstr
benefici
effect
specif
context
influenza
infect
hand
observ
studi
highlight
associ
statin
treatment
reduct
allcaus
mortal
patient
hospit
laboratoryconfirm
season
influenza
random
placebocontrol
phase
ii
clinic
trial
aim
evalu
potenti
effect
atorvastatin
reduc
sever
ill
influenzainfect
patient
current
undergo
nitazoxanid
anoth
illustr
serendipit
repurpos
approach
probabl
one
promis
exampl
nitazoxanid
thiazolid
antiinfect
initi
licens
treatment
parasit
infect
antiinfluenza
properti
first
document
rossignol
et
al
interestingli
propos
mode
action
nitazoxanid
toward
influenza
clearli
distinct
design
initi
indic
act
posttransl
level
select
block
matur
viral
glycoprotein
ha
consecut
impact
intracellular
traffick
insert
host
plasma
membran
drug
present
potent
antivir
activ
larg
panel
circul
strain
effect
nitazoxanid
treat
patient
noncompl
influenza
success
phase
iibiii
trial
current
assess
phase
iii
clinic
trial
llysin
acetylsalicylateglycin
modifi
version
antiinflammatori
drug
acetylsalicyl
acid
asa
licens
intraven
inhal
deliveri
current
investig
antiinfluenza
treatment
result
mix
serendipit
targetbas
repurpos
strategi
initi
shown
asa
interest
antivir
effect
influenza
virus
vitro
vivo
via
inhibit
nfkb
activ
kinas
ikkb
neg
impact
influenza
vrnp
transport
releas
infecti
viral
particl
howev
due
pharmacokinet
limit
asa
lasag
modifi
version
improv
stabil
toler
develop
like
asa
molecul
also
demonstr
antivir
activ
sever
human
avian
influenza
virus
vitro
mous
infect
model
inhal
lasag
result
reduc
lung
viral
titer
protect
mice
lethal
infect
recent
phase
ii
proofofconcept
studi
compar
lasag
versu
placebo
patient
sever
influenza
patient
receiv
tamiflu
standard
care
treatment
demonstr
aerosol
lasag
improv
time
symptom
allevi
compar
placebo
despit
absenc
statist
signific
reduct
viral
load
lasagtr
group
naproxen
constitut
nice
exampl
insilico
targetbas
strategi
identif
new
antivir
lejal
et
al
use
structurebas
model
approach
identifi
drug
interest
direct
nucleoprotein
np
influenza
viru
use
xray
structur
rnafre
np
prototyp
insilico
screen
focus
defin
specif
site
np
structur
identifi
naproxen
known
inhibitor
induc
cyclooxygenas
type
commonli
use
nonsteroid
antiinflammatori
drug
identifi
molecul
shown
antivir
properti
influenza
viru
vitro
vivo
recent
naproxen
analog
improv
efficaci
develop
show
high
level
inhibit
nprna
nppolymeras
subunit
pa
complex
without
parallel
inhibit
interestingli
contrast
exampl
drug
repurpos
strategi
exampl
naproxen
remain
virustarget
futur
work
determin
drug
present
achil
heel
classic
antivir
regard
select
antivir
resist
last
two
exampl
chapter
midodrin
diltiazem
identifi
influenza
antivir
context
insilico
assist
strategi
base
transcript
profil
emerg
approach
drug
repurpos
base
signatur
match
consist
compar
specif
characterist
cellular
diseas
approach
mostli
base
transcriptom
data
success
exploit
identifi
drug
repurpos
opportun
larg
rang
therapeut
area
notabl
field
oncolog
rare
diseas
group
first
transpos
approach
field
viral
infecti
diseas
thank
develop
democrat
dnamicroarray
recent
rnaseq
techniqu
proofofconcept
studi
use
vitro
model
infect
postul
host
global
gene
express
profil
consid
fingerprint
signatur
specif
cell
state
includ
infect
drug
treatment
hypothes
screen
databas
compound
counteract
virogenom
signatur
could
enabl
rapid
identif
effect
antivir
among
molecul
identifi
silico
midodrin
adrenerg
alpha
receptor
agonist
wide
use
treat
hypotens
demonstr
interest
vitro
antivir
activ
result
prompt
phase
ii
clinic
evalu
midodrin
treatment
uncompl
season
flu
primari
care
center
base
previou
proofofconcept
obtain
vitro
gene
express
profil
improv
strategi
analyz
upper
respiratori
tract
clinic
sampl
collect
cohort
influenza
patient
determin
respect
transcriptom
signatur
perform
insilico
drug
screen
identifi
list
candid
bioactiv
molecul
signatur
anticorrel
patient
acut
infect
state
potenti
antivir
properti
select
marketapprov
molecul
firstli
valid
vitro
effect
compound
compar
oseltamivir
treatment
influenza
viru
infect
mice
physiolog
vitro
model
reconstitut
human
airway
epithelia
result
notabl
highlight
diltiazem
calcium
channel
blocker
use
antihypertens
drug
promis
repurpos
hosttarget
inhibitor
influenza
infect
ongo
french
multicent
random
clinic
trial
investig
effect
diltiazemoseltamivir
bitherapi
compar
standard
oseltamivir
monotherapi
treatment
sever
influenza
infect
intens
care
unit
flunext
trial
concept
antivir
combin
therapi
origin
pioneer
antiretrovir
treatment
primari
goal
prevent
least
delay
emerg
drug
resist
via
target
multipl
step
viral
cycl
anoth
expect
complementari
goal
obtain
addit
synergist
effect
combin
drug
doubletrigg
effect
increas
effect
andor
reduc
dosag
context
influenza
infect
combin
classic
antivir
mostli
na
inhibitor
explor
sever
research
group
includ
rel
mix
conclus
exampl
mous
model
combin
oseltamivir
zanamivir
shown
superior
zanamivir
monotherapi
context
influenza
infect
clinic
trial
conduct
pandem
combina
trial
fail
demonstr
whether
oseltamivirzanamivir
combin
therapi
improv
reduc
effect
oseltamivir
alon
treatment
influenza
infect
commun
patient
clinic
investig
shown
greater
effect
combin
therapi
reduc
influenza
transmiss
altern
antivir
strategi
treatment
influenza
infect
includ
relat
drug
repurpos
target
host
instead
viral
determin
emerg
trend
consist
propos
innov
therapi
combin
classic
antivir
hosttarget
drug
start
show
promis
result
exampl
belardo
et
al
demonstr
cell
culturebas
assay
use
differ
human
avian
model
combin
na
inhibitor
nitazoxanid
present
synergist
antiinfluenza
effect
convinc
result
also
obtain
use
combin
treatment
includ
naproxen
clinic
trial
enrol
hospit
patient
infect
influenza
combin
therapi
naproxen
oseltamivir
clarithromycin
show
improv
efficaci
term
hospit
stay
durat
patient
mortal
compar
oseltamivir
treatment
alon
context
evalu
antivir
activ
diltiazem
reconstitut
human
airway
epithelium
model
group
demonstr
diltiazemoseltamivir
combin
treatment
confer
greater
reduct
apic
viral
titer
measur
samedos
monotherapi
mark
delay
viral
product
ongo
french
multicent
random
clinic
trial
investig
effect
diltiazemoseltamivir
bitherapi
compar
standard
oseltamivir
monotherapi
treatment
sever
influenza
infect
intens
care
unit
flunext
trial
altogeth
result
plead
favor
use
drug
repurpos
improv
current
standard
care
antiinfluenza
therapi
contrast
technolog
domain
innov
necessari
chase
replac
establish
standard
futur
work
still
necessari
investig
real
impact
novel
host
virustarget
multitherapi
approach
manag
control
emerg
viral
resist
need
find
new
drug
rather
need
find
patient
benefit
exist
drug
say
goe
although
somehow
exagger
statement
summar
pretti
clearli
essenc
behind
drug
repurpos
initi
find
new
indic
alreadyexist
drug
mani
benefit
mainli
improv
costeffect
reduc
risk
shorten
time
market
purpos
review
foster
discuss
drug
repurpos
option
complet
implement
current
antiinfluenza
therapeut
arsen
face
import
need
develop
novel
antivir
strategi
improv
treatment
case
sever
less
prone
select
antivir
resist
regard
identif
valid
differ
complementari
mean
repurpos
drug
incontest
great
interest
notabl
combin
current
classic
virustarget
inhibitor
addit
deposit
data
includ
neg
result
public
databas
encourag
would
facilit
effort
repurpos
licens
orphan
drug
consecut
increas
chanc
find
new
effici
antivir
drug
grow
number
academ
group
pharmaceut
compani
work
emerg
field
certainli
see
interest
progress
effici
novel
antiinfluenza
therapi
reach
regulatori
market
approv
near
futur
context
global
world
face
major
vicissitud
includ
popul
dynam
climat
chang
multipl
emergencereemerg
zoonot
virus
effect
reaction
forc
classic
de
novo
develop
antivir
challeng
despit
inher
limit
drug
repurpos
offer
larg
palett
possibl
rapidli
effici
find
new
antivir
drug
ap
bp
ot
mrc
coinventor
two
patent
applic
file
inserm
claud
bernard
lyon
laval
univers
hospic
civil
de
lyon
repurpos
drug
antiinfluenza
agent
